Profile:
Axiogenesis’ core business is pharmaceutical biotechnology in the production of stem cell-based assays and customized cell lines that enable drug development. We have developed a proprietary platform to identify drug candidates in Hypertrophic Cardiomyopathy (HCM). Our assays are based on pure, in vitro differentiated, stem cell-derived cell types. Our main products are cardiomyocytes, smooth muscle cells and endothelial cells. Axiogenesis CRO services include cardiac toxicity, cytotoxicity, embryotoxicity, and human cardiac electrophysiology (MEA and Patch Clamp analysis). These innovative and proprietary assays accelerate and improve drug candidate selection, lower costs and increase overall drug development efficiency.